AstraZeneca(US:AZN) Xin Hua Cai Jing·2025-05-17 03:15Group 1 - The 2025 Taihu Bay Life and Health Future Conference was held in Wuxi, Jiangsu, where AstraZeneca engaged in innovative collaborations to promote a scientific innovation ecosystem and high-quality industry development [2] - AstraZeneca's China General Manager emphasized Wuxi as a strategic hub for the company's operations in China, aiming to deepen its presence and foster international cooperation to benefit patients globally [2] - AstraZeneca, in collaboration with Wuxi High-tech Zone and Ruijin Hospital, launched the "Ruijin Yangtze River Delta Metabolic Industry Park" to address patient needs in the metabolic field and enhance the synergy between clinical, industrial, and policy aspects [2] Group 2 - AstraZeneca has been operating in China since 1993, focusing on various therapeutic areas and has introduced over 40 innovative drugs to the market [3] - The company has established two of its six global strategic R&D centers in China, with over 200 projects in its Chinese R&D pipeline, aiming to launch 20 global innovative drugs by 2030 [3] - AstraZeneca has partnered with CICC to establish the AstraZeneca CICC Medical Industry Fund, with approximately $550 million under management, investing in 27 Chinese innovative companies [4] Group 3 - AstraZeneca has invested over $1 billion in Wuxi, establishing a production base, a regional packaging center, and a logistics center [4] - A new small molecule drug factory with an investment of $475 million is under construction in Wuxi, which will primarily produce innovative cardiovascular drugs from AstraZeneca's pipeline [4]